Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network

Liver Transplantation

Volumn 22, Issue 1, 2016, Pages 24-33

  Brown, Robert S ^a   O'Leary, Jacqueline G ^b   Reddy, K Rajender ^c   Kuo, Alexander ^d   Morelli, Giuseppe J ^e   Burton, James R ^f   Stravitz, R Todd ^g   Durand, Christine ^h   Di Bisceglie, Adrian M ⁱ   Kwo, Paul ^j   Frenette, Catherine T ^k   Stewart, Thomas G ^l   Nelson, David R ^e   Fried, Michael W ^l   Terrault, Norah A ^m  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF FLORIDA   (United States)

^f UNIVERSITY OF COLORADO   (United States)

^g VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ SAINT LOUIS UNIVERSITY   (United States)

^j INDIANA UNIVERSITY   (United States)

^k SCRIPPS CLINIC   (United States)

^l UNIVERSITY OF NORTH CAROLINA   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; INTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; ANTIVIRUS AGENT;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; ASPIRATION PNEUMONIA; BILE DUCT DISEASE; BLOOD TRANSFUSION; CLINICAL RESEARCH; COMBINATION CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; DECOMPENSATED LIVER CIRRHOSIS; DEHYDRATION; DISEASE REGISTRY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; ESOPHAGUS STENOSIS; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; GRAFT RECIPIENT; HEADACHE; HEMATOMA; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HYPERGLYCEMIA; HYPERVOLEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFESTATION; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER DISEASE; LIVER GRAFT; LIVER GRAFT REJECTION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; NAUSEA; PRIORITY JOURNAL; PRURITUS; RASH; RNA VIRUS; SUICIDE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; VOMITING; CLINICAL TRIAL; GENETICS; LIVER TRANSPLANTATION; LONGITUDINAL STUDY; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; REGISTER;

AGED; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C; HUMANS; IMMUNOSUPPRESSION; LIVER TRANSPLANTATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; REGISTRIES; SIMEPREVIR; SOFOSBUVIR; TREATMENT OUTCOME;

EID: 84955275730     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.24366     Document Type: Article

References (37)

1. Thuluvath PJ, Guidinger MK, Fung JJ, Johnson LB, Rayhill SC, Pelletier SJ,. Liver transplantation in the United States, 1999-2008. Am J Transplant 2010; 10 (pt 2): 1003-1019.
2. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR,. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-896.
3. Picciotto FP, Tritto G, Lanza AG, Addario L, De Luca M, Di Costanzo GG, et al., Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007; 46: 459-465.
4. Berenguer M, Palau A, Aguilera V, Rayõn JM, Juan FS, Prieto M,. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008; 8: 679-687.
5. Bizollon T, Pradat P, Mabrut JY, Chevallier M, Adham M, Radenne S, et al., Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C. Am J Transplant 2005; 5: 1909-1913.
6. Veldt BJ, Poterucha JJ, Watt KD, Wiesner RH, Hay JE, Kremers WK, et al., Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant 2008; 8: 2426-2433.
7. Crespo G, Carriõn JA, Coto-Llerena M, Mariño Z, Lens S, Pérez-Del-Pulgar S, et al., Combinations of simple baseline variables accurately predict sustained virological response in patients with recurrent hepatitis C after liver transplantation. J Gastroenterol 2013; 48: 762-769.
8. Xirouchakis E, Triantos C, Manousou P, Sigalas A, Calvaruso V, Corbani A, et al., Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies. J Viral Hepat 2008; 15: 699-709.
9. Angelico M, Petrolati A, Lionetti R, Lenci I, Burra P, Donato MF, et al., A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol 2007; 46: 1009-1017.
10. Carriõn JA, Navasa M, García-Retortillo M, García-Pagan JC, Crespo G, Bruguera M, et al., Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007; 132: 1746-1756.
11. Hanouneh IA, Miller C, Aucejo F, Lopez R, Quinn MK, Zein NN,. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy. Liver Transpl 2008; 14: 53-58.
12. Berenguer M, Schuppan D,. Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment. J Hepatol 2013; 58: 1028-1041.
13. Roche B, Sebagh M, Canfora ML, Antonini T, Roque-Afonso AM, Delvart V, et al., Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl 2008; 14: 1766-1777.
14. Berenguer M, Aguilera V, Rubín A, Ortíz C, Jimenez M, Prieto M,. Comparison of two non-contemporaneous HCV-liver transplant cohorts: strategies to improve the efficacy of antiviral therapy. J Hepatol 2012; 56: 1310-1316.
15. Oton E, Barcena R, Moreno-Planas JM, Cuervas-Mons V, Moreno-Zamora A, Barrios C, et al., Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose PEG-interferon and ribavirin. Am J Transplant 2006; 6: 2348-2355.
16. Berenguer M, Aguilera V, Prieto M, Ortiz C, Rodríguez M, Gentili F, et al., Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis. Liver Transpl 2009; 15: 738-746.
17. Berenguer M,. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274-287.
18. Ponziani FR, Annicchiarico EB, Siciliano M, D'Aversa F, Pompili M, Gasbarrini A,. Treatment of hepatitis C in compensated cirrhotic patients is equally effective before and after liver transplantation. World J Gastroenterol 2013; 19: 3255-3262.
19. Verna EC, Saxena V, Burton JR Jr, O'Leary JG, Dodge JL, Stravitz RT, et al.,; for CRUSH-C Consortium. Telaprevir- and boceprevir-based triple therapy for hepatitis C in liver transplant recipients with advanced recurrent disease: a multicenter study. Transplantation 2015; 99: 1644-1651.
20. Burton JR Jr, O'Leary JG, Verna EC, Saxena V, Dodge JL, Stravitz RT, et al., A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. J Hepatol 2014; 61: 508-514.
21. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, et al., Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384: 1756-1765.
22. Forns X, Charlton M, Denning J, McHutchison JG, Symonds WT, Brainard D, et al., Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology 2015; 61: 1485-1494.
23. Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R Jr, et al., An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014; 371: 2375-2382.
24. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr, et al.,; for SOLAR-1 Investigators. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015; 149: 649-659.
25. Gordon SC, Muir AJ, Lim JK, Pearlman B, Argo CK, Ramani A, et al.,; for HCV-TARGET study group. Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET. J Hepatol 2015; 62: 286-293.
26. Ouwerkerk-Mahadevan S, Simion A, Mortier S, Peeters M, Beumont M,. No clinically significant interaction between the investigational HCV protease inhibitor TMC435 and the immunosuppressive agents cyclosporine and tacrolimus. Hepatology 2012; 56 (suppl 1): 231A.
27. Charlton M, Gane E, Manns MP, Brown RS Jr, Curry MP, Kwo PY, et al., Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015; 148: 108-117.
28. Ouwerkerk-Mahadevan S, Vanwelkenhuysen I, Peeters M, Simonts M, Ilsbroux I, Simion A, Witek J,. Significant drug-drug interaction between simeprevir and cyclosporine A but not tacrolimus in patients with recurrent chronic HCV infection after orthotopic liver transplantation: the SATURN study. J Hepatol 2015; 62 (suppl 2): S650.
29. Janssen. http://www.olysio.com/shared/product/olysio/prescribing-information.pdf. Accessed November 4, 2015.
30. Terrault NA, Berenguer M,. Treating hepatitis C infection in liver transplant recipients. Liver Transpl 2006; 12: 1192-1204.
31. Gutierrez JA, Carrion AF, Avalos D, O'Brien C, Martin P, Bhamidimarri KR, Peyton A,. Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients. Liver Transpl 2015; 21: 823-830.
32. Pungpapong S, Aqel B, Leise M, Werner KT, Murphy JL, Henry TM, et al., Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology 2015; 61: 1880-1886.
33. Féray C, Samuel D, Gigou M, Paradis V, David MF, Lemonnier C, et al., An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Hepatology 1995; 22 (pt 1): 1084-1089.
34. Fontana RJ, Hughes EA, Bifano M, Appelman H, Dimitrova D, Hindes R, Symonds WT,. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant 2013; 13: 1601-1605.
35. Reddy KR, Everson GT, Flamm SL, Denning JM, Arterburn S, Brandt-Sarif T, et al., Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with post transpalnt recurrence: Preliminary resutls of a prosepcitve, multicenter study. Hepatology 2014; 60 (suppl 1): 200A.
36. Forns X, Berenguer M, Herzer K, Sterneck M, Donato MF, Andreone P, et al., On-treatment virological response and tolerability of simeprevir, daclatasvir and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation (OLT): Interim data from the phase II SATURN Study. European Association for the Study of the Liver; Vienna, Austria; 2015.
37. Eyster ME, Sherman KE, Goedert JJ, Katsoulidou A, Hatzakis A,. Prevalence and changes in hepatitis C virus genotypes among multitransfused persons with hemophilia. The Multicenter Hemophilia Cohort Study. J Infect Dis 1999; 179: 1062-1069.